A look at how Congress may deal with the issue of biogenerics, with John Calfee, American Enterprise Institute Resident Scholar; Kathleen Jaeger, Generic Pharmaceutical Association CEO and CNBC's Sue Herera
I had questions about who's responsible for safety issues around biogeneric variability. So did John Calfee:
"I think that given the pressure the FDA is under for drug safety, the FDA is going to move very slowly to allow anything purporting to be a generic version of those drugs even if the law is changed opening the way for that kind of thing. And I think that doctors are going to be very slow to switch to those drugs..."
Kathleen Jaeger side steps the issue by saying the process should be ruled by "science." I think science is the hurdle for biogenerics, at least until technology advances.
No comments:
Post a Comment